Tu SS - Search Results

1

Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US.

Wouters OJ, Vogel M, Feldman WB, Beall RF, Kesselheim AS, Tu SS. Wouters OJ, et al. Among authors: tu ss. JAMA. 2024 Dec 24;332(24):2101-2108. doi: 10.1001/jama.2024.16911. JAMA. 2024. PMID: 39585667

2

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.

Olsen A, Beall RF, Knox RP, Tu SS, Kesselheim AS, Feldman WB. Olsen A, et al. Among authors: tu ss. PLoS Med. 2023 Nov 16;20(11):e1004309. doi: 10.1371/journal.pmed.1004309. eCollection 2023 Nov. PLoS Med. 2023. PMID: 37971985 Free PMC article.

3

Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.

Van de Wiele VL, Kesselheim AS, Gleeson D, Lu Z, Tu SS, Rome BN. Van de Wiele VL, et al. Among authors: tu ss. Pharmaceut Med. 2024 Jul;38(4):303-310. doi: 10.1007/s40290-024-00527-w. Epub 2024 Jul 14. Pharmaceut Med. 2024. PMID: 39003670

4

Use of Public Research and Manufacturing Enterprises to Lower Prescription Drug Prices and Increase Innovation.

Moss A, Brown D, Tu SS. Moss A, et al. Among authors: tu ss. J Law Med Ethics. 2024;52(3):750-754. doi: 10.1017/jme.2024.142. Epub 2024 Dec 16. J Law Med Ethics. 2024. PMID: 39676364

5

Clearing Dense Drug-Patent Thickets.

Chao B, Whalen R, Kesselheim AS, Tu SS. Chao B, et al. Among authors: tu ss. N Engl J Med. 2024 Dec 12;391(23):2180-2182. doi: 10.1056/NEJMp2412999. Epub 2024 Nov 27. N Engl J Med. 2024. PMID: 39602623 No abstract available.

6

Characteristics of Academic Inventors on Government-Linked US Drug Patents.

Martin MJ, Gabriele SME, Kesselheim AS, Tu SS. Martin MJ, et al. Among authors: tu ss. JAMA. 2024 Dec 17;332(23):2032-2033. doi: 10.1001/jama.2024.20361. JAMA. 2024. PMID: 39570615

7

Author Correction: The cost of drug patent expiration date errors.

Tu SS, Cheian D, Gabriele S, Rome BN, Kesselheim AS. Tu SS, et al. Nat Biotechnol. 2024 Nov;42(11):1747. doi: 10.1038/s41587-024-02459-x. Nat Biotechnol. 2024. PMID: 39379647 No abstract available.

8

Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.

Tu SS, Kesselheim AS, Chao B. Tu SS, et al. JAMA. 2024 Sep 10;332(10):837-838. doi: 10.1001/jama.2024.14350. JAMA. 2024. PMID: 39133468

9

Improved Production Rates of Hydrogen Generation and Carbon Dioxide Reduction Using Gallium Nitride with Nickel Oxide Nanofilm Capping Layer as Photoelectrodes for Photoelectrochemical Reaction.

Sheu CY, Tu SS, Chang SJ. Sheu CY, et al. Among authors: tu ss. ACS Omega. 2024 Jul 26;9(31):33882-33887. doi: 10.1021/acsomega.4c03729. eCollection 2024 Aug 6. ACS Omega. 2024. PMID: 39130556 Free PMC article.

10

Use of Track One Prioritized Examination for Pharmaceutical Patents.

Tu SS, Feldman WB. Tu SS, et al. JAMA Health Forum. 2024 Jul 5;5(7):e241886. doi: 10.1001/jamahealthforum.2024.1886. JAMA Health Forum. 2024. PMID: 39028656 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters